ETC-1002 (Bempedoic acid) for the management of hyperlipidemia: from preclinical studies to phase 3 trials
Articolo
Data di Pubblicazione:
2019
Citazione:
ETC-1002 (Bempedoic acid) for the management of hyperlipidemia: from preclinical studies to phase 3 trials / M. Ruscica, M. Banach, A. Sahebkar, A. Corsini, C.R. Sirtori. - In: EXPERT OPINION ON PHARMACOTHERAPY. - ISSN 1465-6566. - 20:7(2019 May), pp. 791-803. [10.1080/14656566.2019.1583209]
Abstract:
Tolerability problems in treating hypercholesterolemic patients undergoing statin treatment are of growing concern to physicians and patients, thus underlining the need for an agent with a similar mechanism but minimal side effects. A drug with a somewhat similar mechanism to statins but free of muscular side effects is ETC-1002 (bempedoic acid). It inhibits cholesterol biosynthesis at a step preceding HMG-CoA reductase, i.e. ATP citrate lyase (ACLY). A prodrug, ETC-1002 is converted to the active agent only in liver, not in skeletal muscle, and this may prevent any myotoxic activity. Area covered: The mechanism of ETC-1002 activity is described in detail, considering that ACLY inhibition markedly attenuated atherosclerosis in animal models. Clinical studies are also reported. Expert opinion: Present day LDL-C lowering treatments lead to significant reductions of cardiovascular (CV) events but, at times, the need to interrupt statin treatment appears to be dangerous due to a rapid rise in CV risk. The excellent tolerability of ETC-1002 makes it a useful alternative, either alone or as an adjunct to ezetimibe, for patients with statin intolerance needing to achieve significant CV risk reduction. ETC-1002 is also associated with a marked fall in high-sensitivity C-reactive protein.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
ATP-citrate lyase; ETC-1002; LDL-C; bempedoic acid; cardiovascular disease; hsCRP; non-HDL; statin intolerance
Elenco autori:
M. Ruscica, M. Banach, A. Sahebkar, A. Corsini, C.R. Sirtori
Link alla scheda completa: